Full-Time

Senior Research Associate

LNP Analytical Research and Development

Confirmed live in the last 24 hours

Beam Therapeutics

Beam Therapeutics

501-1,000 employees

Develops precision genetic medicines using base editing

Biotechnology
Healthcare

Senior

Cambridge, MA, USA

Category
Lab & Research
Life Sciences
Required Skills
Data Analysis
Requirements
  • B.S. degree in a relevant discipline (analytical chemistry, biochemistry, biotechnology, or related fields).
  • 6+ years (depending on title) industry experience (including biotech, biopharma, CRO, CDMO) with hands on experience in cell and gene therapy analytical development or QC.
  • Hands on experience on analytical method development and sample testing at GMP or non-GMP environments.
  • Experience with analysis of RNAs, lipids, and lipid nanoparticles (LNPs) is highly desirable and will be key to the success in this role.
  • Working experience with at least one or several of the analytical techniques is required: HPLC (IPRP, SEC, IEX), capillary gel electrophoresis, fluorescence-based RNA quantitation. Experience with qPCR, DNA and RNA extraction, ELISA, UV spectrophotometry, DLS, MALS, mass spectrometry, and compendial testing will be a plus.
  • Knowledge of ICH/USP guidelines.
  • Familiarity with data analysis software such as Empower, Openlab, Chromeleon, and statistical software such as JMP. Experience with LIMS system.
  • Team player with excellent oral and written communication skills.
  • Independently motivated, detail-oriented scientist with excellent critical thinking and problem-solving abilities.
  • Excellent organizational skills towards multi-tasking in an extremely fast-paced environment with changing priorities.
Responsibilities
  • Develop and optimize analytical methods for RNA and LNP products to support Beam’s early and late phase method development requirements as well as establish platform analytical approaches.
  • Execute analytical sample testing to support Beam’s internal and external development on LNP selection, optimization, production, and final DS/DP release and characterization.
  • Work with cross-functional groups including LNP discovery, LNP process development, and LNP CMC team in various aspects of method development, transfer, characterization, comparability, and investigation.
  • Support external testing labs as analytical SME.
  • Generate materials to support assay feasibility test and GMP qualification at CDMOs, CROs, and internal GMP and non-GMP labs.
  • Contribute to technical transfer of analytical methods both internally and to external vendors.
  • Coordinate routine sample testing including requests from Process Development, Research and Development groups, and external vendors.
  • Author and review SOPs, technical reports, and assist in the preparation of CMC regulatory submissions.
  • Analyze, track, and trend data to monitor analytical assays and ensure consistency in assay performance.
  • Maintain detailed documentation of experiments in ELN system.
  • Live Beam Therapeutics core values of being part of a community of fearless innovators, being rigorous and honest in our research, listening with open minds, and committed to each other.

Beam Therapeutics develops precision genetic medicines using a technique called base editing, which allows for precise modifications to the genetic code to potentially correct mutations that lead to serious diseases. Their primary focus is on treating genetic disorders, such as sickle cell disease, with the aim of providing lifelong cures rather than temporary solutions. The company invests significantly in research and development to create new therapies and generates revenue through partnerships, licensing agreements, and future commercialization of their treatments. Beam Therapeutics distinguishes itself from competitors by its commitment to rigorous scientific development and a values-driven approach, emphasizing the importance of its expert team. The ultimate goal of the company is to advance genetic medicine to offer lasting cures for patients.

Company Stage

IPO

Total Funding

$215.9M

Headquarters

Cambridge, Massachusetts

Founded

2017

Growth & Insights
Headcount

6 month growth

2%

1 year growth

0%

2 year growth

-6%
Simplify Jobs

Simplify's Take

What believers are saying

  • Beam's $250M deal with Eli Lilly boosts financial resources and strategic support.
  • Growing demand for precision therapies aligns with Beam's base editing focus.
  • Advancements in AI-driven drug discovery enhance Beam's R&D capabilities.

What critics are saying

  • Increased competition from CRISPR Therapeutics threatens Beam's market share.
  • Recent restructuring and 20% staff reduction may delay new therapy development.
  • New CFO appointment could lead to strategic shifts or financial instability.

What makes Beam Therapeutics unique

  • Beam Therapeutics uses base editing, a precise genetic modification method.
  • The company focuses on lifelong cures for genetic disorders, not just symptom relief.
  • Beam's base editing targets single genome bases without double-stranded DNA breaks.

Help us improve and share your feedback! Did you find this helpful?